November and December 2014 were exciting months for Seke North and St. Mary’s CRSs, as they began screening and enrollment into IMPAACT P1078. This study is looking to see if INH (Isonizaid, a medication used to treat or prevent tuberculosis) protects HIV-infected pregnant women and their infants from contracting tuberculosis, and if starting INH during […]
Author Archive | wpadmin
NIH-sponsored study identifies superior drug regimen for preventing mother-to-child HIV transmission
For HIV-infected women in good immune health, taking a three-drug regimen during pregnancy prevents mother-to-child HIV transmission more effectively than taking one drug during pregnancy, another during labor and two more after giving birth, an international clinical trial has found. The ongoing PROMISE (Promoting Maternal-Infant Survival Everywhere) study also has found that one triple-drug regimen […]
HPTN 076: Injectable PrEP
Client-centered models of HIV prevention for women which employ Pre Exposure Prophylaxis (PrEP) examine both drug effectiveness but also drug delivery. It has become critical to understand whether available delivery options are likely to be utilized given individual risk, preference and lifestyle. Most frequently offered as a pill, vaginal film, vaginal ring or gel, injectable […]
UZCHS-CTRC to Conduct P1115, “Mississippi Baby” Proof-of-Concept Study
In 2013, a case of HIV remission was reported in a U.S. born child (known as the “Mississippi Baby”) who was treated with three drug ART by 31 hours of life for high-risk HIV exposure from a mother with untreated HIV infection. In this infant, viral load detection reached undetectable levels by 28 days of […]
James Kublin, MD, MPH, Executive Director of HVTN, Visits Harare
HIV Vaccine Trials Network (HVTN) Executive Director, James Kublin, MD, MPH, lead a one-day training on 3 October 2014, in Harare, aimed at orienting Zimbabwe national regulators to the work of the HVTN, the P5 Initiative in Southern Africa, and Phase I clinical trials the network is planning for implementation in the region. The P5 […]
Seke South CRS Selected as a Protocol Specific Site for the HIV Vaccine Trials Network
UZCHS-CTU’s Seke South CRS has been officially selected as a protocol specific site by the US National Institutes of Health’s HIV Vaccine Trials Network (HVTN). The HVTN’s mission is to facilitate the process of testing preventative vaccines against HIV/AIDS and is a global leader in vaccine development. These will be the first ever HIV-related vaccine […]
1994 – 2014: UZCHS-CTRC Celebrates 20 Years of Cutting Edge Research in Collaboration with UCSF
2014 marked the 20th Anniversary of UZCHS-CTU and collaborations with UCSF in Harare, Zimbabwe. Since its inception in 1994, our studies have helped to shape national and global responses to the HIV/AIDS pandemic, and have defined policies and standards regarding the course of HIV acquisition, prevention, treatment, and care. Some examples include groundbreaking research in […]
UZCHS-CTRC Launches CHIC 02A
Linking HIV prevention strategies to contraception has a significant potential for public health benefit. However, many large observational studies to date have indicated an association between the use of combined oral contraceptives or depot medroxyprogesterone acetate and HIV acquisition and transmission. To date, little research has been designed to try and explain if hormonal contraceptive […]
UZ-CTRC-Clinical Trials Unit Awarded Continued Funding Into 2021
UZ-CTRC, in collaboration with UCSF, has been awarded continued Clinical Trials Unit (CTU) funding from the US National Institute of Allergy and Infectious Diseases (NIAID) to continue conducting high quality HIV treatment and prevention studies through 2021. The CTU will continue to operate seven clinical research sites, which operate under four NIAID sponsored research networks: […]
